Pharmacological inhibition of DNA-PK stimulates Cas9-mediated genome editing by Francis Robert et al.
Robert et al. Genome Medicine  (2015) 7:93 
DOI 10.1186/s13073-015-0215-6RESEARCH Open AccessPharmacological inhibition of DNA-PK
stimulates Cas9-mediated genome editing
Francis Robert1, Mathilde Barbeau1, Sylvain Éthier1, Josée Dostie1 and Jerry Pelletier1,2,3*Abstract
Background: The ability to modify the genome of any cell at a precise location has drastically improved with the
recent discovery and implementation of CRISPR/Cas9 editing technology. However, the capacity to introduce
specific directed changes at given loci is hampered by the fact that the major cellular repair pathway that occurs
following Cas9-mediated DNA cleavage is the erroneous non-homologous end joining (NHEJ) pathway. Homology-
directed recombination (HDR) is far less efficient than NHEJ and makes screening of clones containing directed
changes time-consuming and labor-intensive.
Methods: We investigated the possibility of pharmacologically inhibiting DNA-PKcs, a key player in NHEJ, using
small molecule inhibitors (NU7441 and KU-0060648), to ameliorate the rates of HDR repair events. These
compounds were tested in a sensitive reporter assay capable of simultaneously informing on NHEJ and HDR, as
well as on an endogenous gene targeted by Cas9.
Results: We find that NU7441 and KU-0060648 reduce the frequency of NHEJ while increasing the rate of HDR
following Cas9-mediated DNA cleavage.
Conclusions: Our results identify two small molecules compatible for use with Cas9-editing technology to improve
the frequency of HDR.Background
The bacterial innate immune CRISPR (clustered regu-
larly interspaced short palindromic repeat) system has
emerged as a powerful molecular tool for genome engin-
eering [1–4]. The key components of this system are a
Cas9 endonuclease and a bifunctional single guide (sg)
RNA. The sgRNA binds a DNA target site through se-
quence complementarity with the first approximately 20
5’ nucleotides whereas a 3’ aptameric domain is respon-
sible for recruiting Cas9 to the genomic address [1]. The
presence of an 5’NGG3’ protospacer adjacent motif
(PAM) located immediately 3’ of the target sequence
complement is the only essential feature of the target
recognition site [5]. Cas9 will generate double-stranded
breaks (DSB) at the target site which are repaired by the
erroneous non-homologous end-joining (NHEJ) pathway* Correspondence: jerry.pelletier@mcgill.ca
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priate target-homologous donor template is supplied in
trans, by homology directed-repair (HDR) [6, 7].
NHEJ is initiated by a DSB leading to recruitment of a
Ku70/80 heterodimer and the catalytic subunit of DNA-
dependent protein kinase (DNA-PKcs). This tethers the
two ends and a series of subsequent reactions result in re-
section, extension, and ligation [8]. In HDR, the DSB
break is processed to a 3’ single-stranded overhang and a
different set of repair proteins stimulate strand invasion
by a donor homologous template, followed by repair [8].
In general, NHEJ is the more frequently observed repair
pathway when using Cas9-mediated genome engineering,
even in the presence of a donor HDR template [9–12].
Identifying cells of interest following HDR-directed editing
is a labor-intensive and time-consuming process involving
screening of individual clones to identify appropriate,
correctly modified cells.
Improving HDR efficiency would significantly reduce
the downstream workload involved in identifying appro-
priate clones of interest. Cell lines deficient for NHEJ
components have significantly elevated levels of HDRe is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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cesses [13]. Hence suppression of the NHEJ key enzymes
Ku70, Ku80, or DNA Ligase IV has been shown to
stimulate Cas9-mediated HDR at the expense of NHEJ
[14, 15]. A second strategy takes advantage of the fact that
NHEJ occurs throughout the cell cycle whereas HDR-
mediated repair is temporally restricted to late S and G2
phases [16]. Timed delivery of Cas9 protein and sgRNAs
into nocodazole-mediated M phase synchronization of
cells has been shown to increase HDR events [17]. Also, a
recent unbiased screen of approximately 4,000 small mol-
ecules identified L755507 and Brefeldin A as capable of
stimulating HDR, although the mechanism of action was
not elucidated [18]. It has been recognized that DNA-
PKcs can suppress HDR events following generation of a
DSB [19]. The reliance of NHEJ on DNA-PKcs has
prompted the assessment of DNA-PKcs mutants or small
molecule inhibitors of DNA-PKcs on HDR following DSB
induction – events that have been reported to increase
HDR rates [20]. This led us to directly assess if pharmaco-
logical inhibitors of DNA-PKcs would be compatible with
Cas9 editing tools and could be used to favor HDR repair
events while restricting NHEJ-mediated mutagenesis
events. We identified two small molecules compatible for
use with Cas9-editing technology that improve the fre-
quency of HDR while reducing NHEJ mutagenic events.
Methods
General methods
HEK293/17 (obtained from ATCC) and Arf−/− MEFs (a
kind gift of Dr. S. Lowe, Memorial Sloan Kettering Can-
cer Center) were maintained in DMEM supplemented
with 10 % fetal bovine serum, 100 U/mL penicillin/
streptomycin, and 2 mM glutamine. Plasmids were deliv-
ered to HEK293/17 cells by calcium phosphate transfection
and to Arf−/− MEFs by nucleofection using the Amaxa
nucleofector I (Lonza, Walkersville, MD, USA). Plasmids
pQCiG-Rosa, pQCiG-TLR, pQCiG-p53-1, pQCiG-p53-3,
pLC-ROSA, or pLC-TLR have been described previously
[12, 21]. The pCVL Traffic Light Reporter 2.1 and pRRL
SFFV d20GFP.T2A.mTagBFP donor were purchased from
Addgene. NU7441 and KU-0060648 were purchased from
Selleckchem (Houston, TX, USA). Nutlin-3a was obtained
from Sigma (St. Louis, MO, USA) and SCR7 was from
Selleckchem (Burlington, ON, Canada). All compounds
were resuspended in DMSO and stored at −80 °C. siRNAs
targeting DNA-PKcs, PI3K-p110α, Ku70, Ku80, and the
DNA Ligase IV mRNA were purchased from Dharmacon
(Lafayette, CO, USA), resuspended in the company’s resus-
pension buffer to 10 mM and stored at −80 °C. For
γ-irradiation, 293/TLR cells were plated at 25 % confluency
and the next day were treated with DNA-PK inhibitors
(2 μM NU7441 or 250 nM KU-0060648) for 1 h followed
by 4 GY of γ-irradiation. After 30 min, the cells wereharvested and extracts prepared and subjected to SDS-
PAGE, followed by probing western blots using anti-eEF2
(Cell Signaling Technology; Beverly, MA, USA) and anti-
p-H2AX (Upstate Biotechnology; Lake Placid, NY, USA).
Compounds toxicity was determined using cell titer glow
(Promega, Madison, WI, USA).
TLR
The TLR assay was performed essentially as described
by Certo et al. [22]. The presence of blue fluorescent
protein (BFP) in the pRRL SFFV d20GFP.T2A.mTagBFP
donor template plasmid allowed corrections for transfec-
tion efficiencies to be made. In all experiments, back-
ground fluorescence from non-transfected (<0.05 %)
cells was subtracted from the values obtained from
transfected cells. When reporting NHEJ efficiencies, we
multiplied the value obtained by quantitating the
mCherry+ cells by 3 since only one out of three repair
events is expected to yield a ΔeGFP-T2A-mCherry
fusion in the correct frame to generate mCherry+ cells.
Transfections were performed in 6-well plates by the
calcium-phosphate method using 2 μg of Cas9/sgRNA
expression vector with 1 μg of donor plasmid or 0.1 μM
donor oligonucleotide. Plasmids pcDNA-E1B55K and
pcDNA-E4Orf6 were a kind gift from Dr. Phil Branton
(Biochemistry Dept., McGill University, Montreal, QC,
Canada). One microgram of pcDNA-E1B55K and
pcDNA-E4Orf6, or of the pcDNA-3.1 control vector,
were co-transfected with 2 μg of Cas9/sgRNA expression
vector and 1 μg of donor plasmid. For siRNA experiments,
20 nM of each siRNA was transfected using lipofectamine
following the manufacturer’s recommendations (Invitro-
gen, Carlsbad, CA, USA). Genome editing efficiency was
determined by flow cytometry 5 days later. Knockdown
efficiency was monitored by western blotting 48 h follow-
ing transfections using antibodies directed to PI3K-p110α
(Cell Signaling Technology; Beverly, MA, USA), DNA-PK
(Cell Signaling Technology; Beverly, MA, USA), Ku70
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), Ku80
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), or
DNA Ligase IV (Abcam Inc., Cambridge, MA, USA).
Antibodies directed to adenovirus E1B55K and E4Orf6
were a kind gift from Dr. Phil Branton.
Ion torrent sequencing
Following nucleofection of Arf−/− MEFs with Cas9/sgp53
expression vectors, cells were allowed to recover for
16 h at which point 2 μM NU7441 or 250 nM KU-
0060648 was added to the media followed by a 48 h
incubation. Cells were then washed with PBS, media
containing 5 μM Nutlin-3a added, and cells maintained
for an additional 8 days. Genomic DNA was isolated by
resuspending the cells in 500 μL DNA extraction buffer
(0.2 % SDS, 5 mM EDTA, 200 mM NaCl, 100 mM Tris-
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16 h. The DNA was recovered by precipitation with one
volume of isopropanol, washed with 70 % EOH, air-
dried, and resuspended in water. Selected genomic re-
gions targeted by sgp53-1 and sgp53-3 were amplified
using barcoded primers with engineered adaptor regions
(Table 1) and Phusion HiFi polymerase (NEB; Beverly,
MA, USA) using five cycles at an annealing temperature
of 56 °C followed by 20 cycles at an annealing
temperature of 68 °C. PCR products were purified
using Ampure XP beads (Beckman; Fullerton, CA,
USA) and the samples were quantified using the
Quant-iT PicoGreen dsDNA Assay Kit (P11496, Life
Technologies Inc.; Rockville, MD, USA), pooled in
equimolar ratios and sequenced on an Ion Torrent
Personal Genome Machine (PGM) as recommended
by the manufacturer (Life Technologies; Rockville,
MD, USA). Sequence reads were processed and ana-
lyzed as previously described [12].
Results and discussion
To simultaneously monitor NHEJ and HDR repair pro-
cesses following induction of a DSB, we utilized the con-
venient and robust ‘Traffic Light Reporter’ (TLR) assay
developed by Scharenberg and colleagues [22]. This sys-
tem relies on HDR-mediated repair to generate func-
tional enhanced green fluorescent protein (eGFP) and
NHEJ to enable mCherry production (Fig. 1a). We
sought to validate our assay conditions for reporting on
HDR and NHEJ events following suppression of DNA
Ligase IV or DNA-PKcs using siRNAs, since suppression
of these have been previously shown to increase HDR
levels [22–24]. HEK 293 T/17 cells transduced with the
TLR reporter (hereafter referred to as 293/TLR) were
first transfected with either a scrambled siRNA or siR-
NAs targeting DNA-PKcs or DNA Ligase IV (Fig. 1b).
Twenty-four hours later, Cas9/sgRNA expression vectors
targeting the TLR eGFP cistron (sgGFP) in the presence
of an eGFP homologous repair template were introduced
(Fig. 1a, b). Flow cytometry analysis revealed that HDR
occurred in about 4 % of the cells while NHEJ occurred
in about 25–30 % of the cell population (Fig 1c, d). The
analysis also revealed that knockdown of DNA Ligase IV
or DNA-PKcs stimulated HDR approximately three-fold
while reducing NHEJ (Fig 1c, d). We note that HDR effi-
ciencies have been reported to be much higher than ob-
served here [22, 25, 26]. Although we do not understand
the basis for these differences, it might be attributable to
the editing tools used, differences in ratios of donor ver-
sus nuclease-expressing vector used, and/or sensitivity of
methodology used to score the genome editing events.
These results encouraged us to assess if chemical in-
hibition of DNA-PKcs would similarly affect HDR and/
or NHEJ efficiency. We chose two well-characterizedpharmacological inhibitors of DNA-PKcs, NU7441 [27]
and KU-0060648 [28]. We first verified that both inhibi-
tors were able to block DNA-PKcs kinase activity at
non-toxic concentrations (Additional file 1: Figure S1A)
following γ-irradiation of 293/TLR cells by monitoring
phospho-H2AX level (Fig. 1e, compare lanes 3 and 4 to
1 and 2). To verify if these inhibitors could affect Cas9-
mediated genome editing outcome, we transfected 293/
TLR cells with Cas9 vectors expressing sgRNAs target-
ing either the neutral Rosa26 locus or the TLR eGFP
cistron and exposed cells to NU7441 or KU-0060648
16 h post transfection (Fig. 1b). As expected, no signifi-
cant editing at the TLR locus was apparent in the pres-
ence of Cas9 and the Rosa26 sgRNA (Fig. 1f ). In
contrast, the presence of Cas9 and the sgGFP yielded a
significant proportion of mCherry+ cells due to NHEJ
repair. Supplying a GFP repair template in trans resulted
in approximately 2 % of the cells expressing GFP as a
result of HDR-driven events (Fig. 1f – top right panel).
The addition of NU7441 or KU-0060648 to cells follow-
ing introduction of the Cas9/sgGFP editing system and
the ΔGFP repair template caused a decrease of approxi-
mately 40 % in NHEJ events which was accompanied by
an approximately two-fold stimulation in HDR (Fig. 1f,
g). This effect was dose-dependent and reached a max-
imum at approximately 2.0 μM for NU7441 and 250 nM
for KU-0060648 (Fig. 1g). Higher concentrations of
either compounds were not well tolerated (Additional
file 1: Figure S1). NU7441 or KU-0060648 are not select-
ive for only DNA-PKcs, but also target PI3K, since both
enzymes share highly homologous catalytic domains
[29]. We therefore used siRNAs to suppress the PI3K-
p110α catalytic subunit and found no evidence on
genome editing outcome indicating that PI3K-p110α
suppression is not mediating the effects of NU7441 or
KU-0060648 (Fig. 1c, d).
We next wished to directly compare the efficiency of
HDR stimulation by NU7441 and KU-0060648 to that of
other tools recently reported to stimulate HDR. These in-
clude the DNA ligase IV inhibitor - Scr7, siRNAs to Ku70
and Ku80, and ectopic expression of the adenovirus 5 pro-
teins E1B55K and E4orf6 [14, 15, 30]. Suppression of Ku70
and Ku80 by siRNAs in the 293/TLR line followed by
introduction of Cas9/sgRNAs decreased NHEJ approxi-
mately 1.6-fold while stimulating HDR nearly two-fold
(Fig. 2a and b) – a level similar to what we observed upon
DNA-PK and DNA Ligase IV knockdown (Fig. 1c, d, and
Fig. 2b). Treatment of 293/TLR cells with Scr7 showed a
comparable effect on editing, namely a slight reduction in
NHEJ and an approximately two-fold stimulation of HDR
(Fig. 2b and Additional file 1: Figure S1A). Co-transfection
of vectors expressing the adenovirus 5 proteins E1B55K
and E4orf6 was the most efficient approach to inhibiting
NHEJ (eight-fold reduction) while stimulating HDR 3.5-
Table 1 Oligonucleotide sequences used in this study
TLR donor sense ACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCATGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCG
TLR donor antisense CGGGGTAGCGGCTGAAGCACTGCACGCCGTAGGTCAGGGTGGTCACGAGGGTGGGCCATGGCACGGGCAGCTTGCCGGTGGTGCAGATGAACTTCAGGGTCAGCTTGCCGT
p53-1 sense donor CCCCAGGCCGGCTCTGAGTATACCACCATCCACTACAAGTACATGTGCAACAGTTCTTGTTGGGGGGCATGAACCGCCGACCTATCCTTACCATCATCACACTGGAAGAC







P53-1 barcoding Reverse oligo: CCTCTCTATGGGCAGTCGGTGATGTCCCTCCAATTTTACACCT
p53-3 sense donor CCACACCTCCAGCTGGGAGCCGTGTCCGCGCCATGGCCATCTACAAAAAGTCCCAACAATGACGGAGGTCGTGAGACGCTGCCCCCACCATGAGCGCTGCTCCGATGGT




















ΔeGFP (+1) mCherry (+3)
T2A


































NU7441 (μM) KU-0060648 (nM)
0.2
5
















































Vehicle (DMSO) Vehicle (DMSO)
+KU-0060648+KU-0060648



















































































































Fig. 1 (See legend on next page.)
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Fig. 1 DNA-PKcs inhibitors stimulate HDR following Cas9 induction of a DSB. a Schematic outline of the Traffic Light Reporter assay. The eGFP
and mCherry open reading frames (ORF) are fused by a ribosome skipping sequence (T2A) where translating ribosomes skip from a Gly to a Pro
codon without forming a peptide bond while maintaining the reading frame to produce two distinct polypeptides [39, 40]. In the TLR, the eGFP
and mCherry ORFs are positioned in different frames and NHEJ repair of a DSB directed to the GFP ORF will, in one out of three events, place ΔeGFP
in frame with mCherry - leading to mCherry production. Since the eGFP ORF contains an insertion harboring a premature termination codon (and
lacks a start codon), its expression can only be recovered upon HDR-mediated repair following delivery of an appropriate homologous template. The
reading frame for each fluorescent protein is indicated in parentheses. b Outline of siRNA and drug treatment protocol. In one set of experiments, the
293/TLR cell line was transfected with the indicated siRNAs (yellow box) and 24 h later expression constructs driving synthesis of Cas9 and sgRNAs
and an eGFP donor template were introduced into the cells. In a second set of experiments, the 293/TLR cell line was first transfected with expression
constructs driving synthesis of Cas9 and sgRNAs and an eGFP donor template. Compounds were added 16 h later (orange box). In both cases, cells
were allowed to propagate for 5 days before FACS analysis. c Knockdown of DNA-PK, DNA Ligase IV, and PI3K-p110α in 293/TLR cells transfected with
the indicated siRNAs. Western blots were probed with antibodies to the indicated proteins. The dashed line separates two different sets of membranes.
d Quantitation of genome editing events in 293/TLR cells transfected with the indicated siRNAs. N = 4; error bars represent S.D. Results are from
biological replicates performed in technical duplicates. Significance (relative to scrambled siRNAs) was calculated using the Student’s t-test: *P ≤0.05;
**P ≤0.01; ns, not significant. e DNA-PK inhibitors prevent H2AX phosphorylation upon γ-irradiation. Cells were pre-incubated with the indicated small
molecules for 1 h followed by 4 GY of γ-irradiation (IR). Extracts for western blotting were prepared from non-irradiated (IR) cells (lane 1) or IR-exposed
cells incubated in the presence of vehicle (lane 2), 2 μM NU77441 (lane 3), and 250 nM KU-0060648 (lane 4). Western blots were probed with anti-
bodies directed to the proteins indicated to the left of the blot. The ratio of p-H2AX and eEF2 band intensities is indicated below the blots. f Flow cy-
tometry analysis of 293/TLR cells transfected with pQCX vectors driving synthesis of Cas9 and sgRNAs targeting Rosa26 or eGFP. When indicated, the
GFP repair template, pRRL SFFV d20GFP.T2A.mTagBFP (ΔeGFP Donor) was also included. NU7441 and KU-0060648 were used at a final concentration
of 2 μM and 250 nM, respectively. Cells were gated for the live population as determined by PI staining. Transfection efficiencies were greater than
70 %. g Quantitation of genome editing events from cells propagated in the presence of the indicated concentrations of DNA-PKcs inhibitors. N = 4;
error bars represent S.D. Results are from biological replicates performed in technical duplicates. Significance (relative to vehicle) was calculated using
the Student’s t-test: *p ≤0.05; **p ≤0.01; ns, not significant
Robert et al. Genome Medicine  (2015) 7:93 Page 6 of 11fold (Fig 2c, d) as previously reported [14]. Combining the
DNA-PKcs inhibitors with either Scr7 or E1B55K/E4orf6
showed an additive effect on HDR (Fig. 2b and d).
Since oligonucleotides have become popular as tem-
plates for directed changes following induction of a DSB
by Cas9 and other gene editing tools [2, 31] we sought
to determine if NU7441 or KU-0060648 could also
stimulate HDR mediated by these much shorter, single-
stranded DNA templates. Both sense and antisense
oligonucleotide (relative to the eGFP ORF) functioned as
repair templates following DSB induction. We noted that
the antisense oligonucleotide led to slightly better repair
efficiencies. This strand bias for the antisense oligo-
nucleotide is not well understood but has been previ-
ously discussed [32]. It may involve steric interference
on the transcribed strand blocking oligonucleotide bind-
ing. We also noted that repair efficiencies with oligonu-
cleotides were approximately 10-fold lower than what
was obtained using a longer double-stranded DNA
template (Fig. 3a). This difference could be due to
variations in transfection efficiencies compared to the
DNA template donor, preferences for longer donor
templates for HDR, and/or stability issues. Nonethe-
less, treatment of 293/TLR cells with NU7441 or KU-
0060648 lead to a three- to four-fold increase in HDR
and an approximately two-fold decrease in NHEJ-
mediated repair events (Fig. 3a, b). These results indi-
cate that DNA-PKcs inhibitors can also be used to
stimulate HDR by oligonucleotide donor templates
while suppressing NHEJ events.One strategy that avoids NHEJ mediated events
altogether is the use Cas9 nickase mutants (for example,
Cas9(D10A) and Cas9(H840A)) since DNA nicks are
repaired by the non-mutagenic base excision repair
(single-strand break repair pathway) process while sup-
porting HDR [33–35]. We therefore asked whether
DNA-PKcs inhibitors would also stimulate genomic
repair induced by a DNA nick. As expected, Cas9(D10A)
or Cas9(H840A) targeting the TLR reporter did not lead
to mutagenic repair (Fig. 3c). The levels of HDR re-
pair obtained with the nickases were lower (approxi-
mately two-fold) than obtained with Cas9 (Fig. 3c)
and this process was not stimulated by either
NU7441 or KU-0060648 (Fig. 3c).
To determine if our results could be extended to an
endogenous locus, we targeted p53 exons 5 and 7 using
two previously characterized sgRNAs (sgp53-3 and
sgp53-1, respectively) [21]. Here, Cas9 and sgp53-1 or
sgp53-3 were introduced into Arf−/− mouse embryonic
fibroblasts (MEFs) in the presence or absence of a corre-
sponding oligonucleotide template designed to introduce
a premature nonsense mutation (Fig. 4a). The oligonu-
cleotides also harbored secondary silent mutations that
enabled us to distinguish between nonsense mutations
arising from HDR rather than fortuitously due to NHEJ
(Fig. 4b). Following p53 targeting and exposure to
NU7441 or KU-0060648, cells harboring p53 mutations
were enriched in the presence of Nutlin-3a, an MDM2
antagonist and activator of p53 [21, 36] (Fig. 4a). Ampli-




































































































































































Fig. 2 HDR stimulation by NU7441 and KU-0060648 is comparable to other HDR enhancing tools. a Western blot showing knock down efficiency
obtained with the siRNAs targeting either Ku70 or Ku80. b Quantitation of genome editing events from cells transfected with pQCiG-TLR and ΔeGFP
donor in the presence of 2 μM NU7441, 250 nM KU-0060648, siRNAs targeting Ku70, Ku80, DNA-PKcs or DNA ligase IV, 1 μM Scr7, or a combination
of Scr7 and 2 μM NU7441 or 250 nM KU-0060648. The HDR and NHEJ values are relative to those obtained with Cas9, sgRNA, and ΔeGFP donor in
the presence of vehicle (DMSO). Results are from biological replicates performed in technical duplicates. Significance (relative to vehicle) was calculated
using the Student’s t-test: *p ≤0.05; **p ≤0.01; ns, not significant. c Western blot showing expression of Adenovirus 5 proteins E1B55K and E4orf6
following transfection into the 293/TLR line. d Quantitation of genome editing efficiencies was as in B except that adenovirus 5 proteins E1B55K and
E4orf6 expression vectors were co-transfected with pQCiG-TLR and ΔeGFP donor plasmids and cultured in presence or absence of 2 μM NU7441 or
250 nM KU-0060648. N = 4; error bars represent S.D. Results are from biological replicates performed in technical duplicates. Significance (relative to ve-
hicle) was calculated using the Student’s t-test: *p ≤0.05; **p ≤0.01; ns, not significant
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quences in each sample (Fig. 4a). Approximately 800,000
reads were recovered from each target site, with ap-
proximately 78 % percent mapping back to the reference
sequence. No mutations above background at either p53
exon were recovered from Cas9/sgRosa26 transfected
cells (data not shown). We observed approximately 1 %
oligo-derived sequences from exons 5 and 7 in the ab-
sence of DNA-PKcs inhibitors and that, as in Fig. 3, the
antisense oligonucleotide donor induced higher HDR
correction efficiency compared to the sense donor oligo-
nucleotide donor. As observed in the 293/TLR line,
both NU7441 or KU-0060648 increased HDR ap-
proximately three-fold in the cell population (Fig. 4c).
These results demonstrate that inhibition of DNA-PKcs can be used to stimulate HDR events at en-
dogenous loci.
Stimulation of HDR following inhibition of DNA-PK
with the small molecule IC86621 has been previously re-
ported [20]. Our experiments extend these results using
additional DNA-PKcs inhibitors by demonstrating their
compatibility for use in conjunction with the Cas9 edit-
ing system (Fig. 1). In addition, we demonstrate that
oligonucleotide-mediated HDR at endogenous loci is
also stimulated by both NU7441 and KU-0060648
(Fig. 4). Although the increase in HDR obtained by treat-
ing cells with NU7441 or KU-0060648 was accompanied
by a decrease in NHEJ, our experiments do not allow us
to ascertain whether the stimulation of HDR is












































































































































































































Fig. 3 HDR directed by oligonucleotide donors are stimulated by DNA-PKcs inhibitors. a Quantitation of genome editing events from cells transfected
with pQCiG-TLR and either ΔeGFP donor (2.5 kbp homology upstream and 1.5 kbp homology downstream of target site) or oligonucleotides (sense or
antisense) (110 nucleotides) spanning the sgGFP target site and exposed to vehicle, 2 μM NU7441, or 250 nM KU-0060648. The HDR and NHEJ values
are relative to those obtained with Cas9, sgRNA, and ΔeGFP donor in the presence of vehicle (DMSO). N = 4; error bars represent S.D. Results are from
biological replicates performed in technical duplicates. Significance (relative to vehicle) was calculated using the Student’s t-test: *p ≤0.05; **p ≤0.01;
ns, not significant. b Representative examples of FACS plot obtained in (a). Note that mCherry+ cells are reporting on only one-third of all NHEJ events.
c Quantitation of genome editing events from experiments performed as described in (a) except using WT Cas9 or the D10A and H840A nickase
variants and the ΔeGFP donor. Values are set relative to editing frequencies observed in 293/TLR cells transfected with WT Cas9 expression vector
and propagated in the presence of vehicle. N = 4; error bars represent S.D. Results are from biological replicates performed in technical duplicates.
Significance (relative to vehicle) was calculated using the Student’s t-test: *p ≤0.05; **p ≤0.01; ns, not significant
Robert et al. Genome Medicine  (2015) 7:93 Page 8 of 11reflects a direct inhibitory role of DNA-PKcs on HDR
[20]. The fact that we did not observe a stimulation of
HDR when nicks were introduced at the target loci
(Fig. 3c) suggests an indirect effect. However, it has re-
cently been reported that HDR mediated by nicks occursvia a pathway that is distinct from that induced by DSBs
and is independent of RAD51 and BRCA2 [35]. Hence,
one would expect a lack of response if the reported cross-
talk between DNA-PKcs and HDR does not extend to the
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Fig. 4 DNA-PK inhibitors stimulate homology-directed repair at the p53 locus. a Outline of experimental approach. b Position of target sites and
partial sequence of oligonucleotides used as repair templates for p53 exons 5 and 7. A schematic representation of the murine p53 locus is shown
with the locations of sgp53-1 and sgp53-3. The sequence of the donor templates for HDR (sgp53-1; 105 nucleotides, sgp53-3; 106 nucleotides) are
indicated with red nucleotides denoting missense mutations and a dash indicating a frameshift mutation leading to a premature stop codon (in bold).
c Fold stimulation of HDR at the sgp53-1 and sgp53-3 sites by NU7441 (2 μM) or KU-0060648 (250 nM). Results are shown as the fraction of all retrieved
mutated sequences that correspond to HDR events in the presence of the DNA-PK inhibitors relative to vehicle. N = 4; error bars represent S.D. Results
are from biological replicates performed in technical duplicates. Significance (relative to vehicle) was calculated using the Student’s t-test: *p ≤0.05;
**p ≤0.01; ns, not significant
Robert et al. Genome Medicine  (2015) 7:93 Page 9 of 11require further in-depth characterization. Although our
work highlights the possibility to use DNA-PKcs inhibi-
tors in order to stimulate HDR following Cas9-mediated
cleavage, it should be kept in mind that inhibition of
DNA-PKcs activity shunts some of the repair into alter-
nate pathways [37], an event that could affect repair fidel-
ity at double-stranded breaks that arise spuriously
throughout the cell cycle.
It has been a significant challenge to obtain small mol-
ecule inhibitors that are selective to members of the
PI3K family (PI3K, ATM, ATR, DNA-PK, and mTOR).KU-0060648 targets both DNA-PKcs and PI3K [28],
whereas NU7441 shows 20-fold higher selective inhib-
ition towards DNA-PK than PI3K in cells [38]. NU7441
appears to have little activity towards ATM and ATR
[38]. Although we cannot formally ruled out that the
results obtained herein are due to off-target effects of
KU-0060648 and NU7441, our results are consistent
with the observation that siRNA-mediated suppression
of DNA-PK also stimulates HDR (Fig. 1d) [22]. Treat-
ment of the 293/TLR reporter line with either rapamycin
or PP242, two mTOR inhibitors, had no effect on NHEJ
Robert et al. Genome Medicine  (2015) 7:93 Page 10 of 11or HDR repair efficiencies, making it unlikely that
KU0060648 and NU7441 are acting through inhibition
of mTOR (data not shown). We also do not think that
KU-0060648 and NU7441 are acting through inhibition
of PI3K since siRNA-mediated suppression of PI3K did
not phenocopy the effects of either compound (Fig. 1f ).Conclusions
Our results indicate that transient pharmacological in-
hibition of DNA-PKcs can be used to stimulated HDR
following Cas9-mediated induction of a DSB, thus
enriching for HDR-mediated repair events. This is ex-
pected to reduce the downstream workload required to
identify cells of interest having incorporated a desired,
directed genomic modification.Additional file
Additional file 1: Figure S1. Toxicity of NU7441, KU-0060648 and Scr7
on the cell lines used in this study. A The 293/TLR line was exposed to
increasing concentrations of NU7441, KU-0060648, and Scr7 for 5 days at
which point the viability of the cells was determined. Viability is plotted
relative to vehicle controls. N = 4; error bars represent S.D. Results are
from biological replicates performed in technical duplicates. Significance
(relative to vehicle) was calculated using the Student’s t-test: *P ≤0.05;
**P ≤0.01; ns, not significant. B Viability of Arf−/− MEFs exposed to NU7441
or KU-0060648. Experiments were performed as for 293/TLR cells in (A).
(PDF 371 kb)
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